CRTAP Human

Cartilage Associated Protein Human Recombinant
Cat. No.
BT2730
Source
Escherichia Coli.
Synonyms
CASP, LEPREL3, OI7, Cartilage-associated protein, CRTAP.
Appearance
Sterile Filtered clear solution.
Purity
Greater than 85% as determined by SDS-PAGE.
Usage
Prospec's products are furnished for LABORATORY RESEARCH USE ONLY. They may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
Shipped with Ice Packs
In Stock
Quick Inquiry

Description

CRTAP Human Recombinant produced in E. coli is. a single polypeptide chain containing 398 amino acids (27-401) and having a molecular mass of 46.4kDa. CRTAP is fused to a 23 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.

Product Specs

Introduction
Cartilage-associated protein (CRTAP) plays a crucial role in the formation and maintenance of healthy collagen, a protein vital for strong bones and connective tissues. This protein participates in modifying collagen after it is produced by cells, helps assemble collagen into fibers in the surrounding spaces, and is involved in transporting collagen within cells. Primarily found in cells responsible for cartilage formation (chondrocytes), CRTAP is particularly important for a specific chemical modification (3-hydroxylation) of collagen. Errors in the gene responsible for producing CRTAP can lead to genetic disorders characterized by fragile bones, known as osteogenesis imperfecta types 7 and 2B.
Description
This product consists of the human CRTAP protein manufactured using E. coli bacteria. The protein is a single chain of 398 amino acids (specifically, amino acids 27 to 401 of the full protein sequence), resulting in a molecular weight of 46.4 kDa. For ease of purification and detection, a 23 amino acid tag (His-tag) is attached to the beginning of the protein. The protein is purified using specialized chromatographic methods to ensure its high quality.
Physical Appearance
A clear solution without any particles that has been sterilized by filtration.
Formulation
The CRTAP protein is supplied in a solution containing 0.5mg of protein per ml. The solution also contains 20mM Tris-HCl buffer (pH 8.0), 0.4M Urea, and 10% glycerol.
Stability
For short-term storage (up to 4 weeks), the product can be stored at refrigerated temperature (4°C). For extended storage, it is recommended to store the product frozen at -20°C. Adding a carrier protein such as HSA or BSA to a final concentration of 0.1% is recommended for long-term storage. Repeated freezing and thawing of the product should be avoided to maintain protein integrity and quality.
Purity
The purity of the CRTAP protein in this product is greater than 85%, as determined by SDS-PAGE analysis.
Synonyms
CASP, LEPREL3, OI7, Cartilage-associated protein, CRTAP.
Source
Escherichia Coli.
Amino Acid Sequence
MGSSHHHHHH SSGLVPRGSH MGSQYERYSF RSFPRDELMP LESAYRHALD KYSGEHWAES VGYLEISLRL HRLLRDSEAF CHRNCSAAPQ PEPAAGLASY PELRLFGGLL RRAHCLKRCK QGLPAFRQSQ PSREVLADFQ RREPYKFLQF AYFKANNLPK AIAAAHTFLL KHPDDEMMKR NMAYYKSLPG AEDYIKDLET KSYESLFIRA VRAYNGENWR TSITDMELAL PDFFKAFYEC LAACEGSREI KDFKDFYLSI ADHYVEVLEC KIQCEENLTP VIGGYPVEKF VATMYHYLQF AYYKLNDLKN AAPCAVSYLL FDQNDKVMQQ NLVYYQYHRD TWGLSDEHFQ PRPEAVQFFN VTTLQKELYD FAKENIMDDD EGEVVEYVDD LLELEETS.

Product Science Overview

Discovery and Significance

Ucma was discovered as a protein highly expressed in the articular cartilage and osteophytes during arthritis. It has been identified as a key player in blocking the activity of ADAMTS aggrecanases, enzymes that contribute to cartilage degeneration. The ability of Ucma to inhibit these enzymes makes it a promising target for therapeutic interventions aimed at preventing cartilage degradation in conditions such as osteoarthritis and rheumatoid arthritis .

Mechanism of Action

Ucma exerts its protective effects on cartilage by physically interacting with ADAMTS5, one of the major aggrecanases involved in cartilage breakdown. This interaction inhibits the aggrecanase activity of ADAMTS5, thereby preventing the degradation of aggrecan, a critical component of the cartilage extracellular matrix. Studies have shown that Ucma can effectively inhibit ADAMTS5-triggered or IL-1β-triggered aggrecanolysis both in vitro and in vivo .

Therapeutic Potential

The therapeutic potential of Ucma lies in its ability to protect cartilage from degradation in inflammatory arthritis. Experimental studies have demonstrated that treatment with recombinant Ucma can inhibit cartilage degeneration and reduce osteophyte formation in animal models of arthritis. This suggests that Ucma could be developed as a novel therapeutic agent for preventing cartilage degradation and promoting cartilage repair in patients with arthritis .

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *

Category

Service

THE BIOTEK
THE BioTek is a global biotech company offering highly purified proteins for research in cancer, apoptosis, development, endocrinology, immunology, neuroscience, proteases, and stem cells.
  • Contact
  • Address: 1925 E Maple Ave, El Segundo, CA 90245 United States
  • Phone : +1 201-285-7826
  • Email : info@thebiotek.com
  • Hours : Mon.-Fri. 9:00 AM - 5:00 PM
© Copyright 2024 Thebiotek. All Rights Reserved.